Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1444192/000095017023031612/acst-20230705.htm
November 2023
October 2023
October 2023
September 2023
August 2023
July 2023
July 2023
June 2023
March 2020
February 2020
February 2020
February 2020
February 2020
February 2020
January 2020
December 2019
November 2019
November 2019
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1444192/000095017023031612/acst-20230705.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Acasti Pharma Inc..
Acasti Pharma Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:
Financial Statements, Disclosures and Schedules
Inside this 8-K Corporate News
Material Contracts, Statements, Certifications & more
Acasti Pharma Inc. provided additional information to their SEC Filing as exhibits
Ticker: ACSTEvents:
CIK: 1444192
Form Type: 8-K Corporate News
Accession Number: 0000950170-23-031612
Submitted to the SEC: Wed Jul 05 2023 4:00:34 PM EST
Accepted by the SEC: Wed Jul 05 2023
Period: Wednesday, July 5, 2023
Industry: Pharmaceutical Preparations